Actively Recruiting
Metabolic Phenotyping for Personalized Obesity Therapy
Led by University Hospital Schleswig-Holstein · Updated on 2025-03-13
80
Participants Needed
1
Research Sites
210 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to develop a simple, clinically applicable method for metabolic phenotyping to personalize obesity therapy in morbidly obese individuals. The underlying concept is that the way a person's resting metabolic rate (RMR) responds to a 24-hour fast can help distinguish between two metabolic phenotypes. Individuals with a "thrifty" metabolism show a significant drop in RMR during fasting, which may make them less responsive to conventional weight loss interventions. In contrast, those with a "spendthrift" metabolism exhibit little to no drop-or even a slight increase-in RMR, suggesting they may lose weight more readily. The trial is designed as a prospective, single-center, longitudinal cohort study involving 20 morbidly obese patients (BMI \>40 kg/m²) who are already participating in a multimodal obesity therapy program. The study is divided into three phases. In the baseline phase, participants undergo comprehensive screening, which includes physical examinations, blood tests, and body composition assessments. RMR is measured using indirect calorimetry both before and after a 24-hour fasting period, and a device (Lumen™) is used to assess whether the body is primarily burning carbohydrates or fats. After the fasting measurements, participants perform a low-protein meal test by consuming a specially calibrated chocolate beverage. Their RMR is then monitored at several time points to determine the energy required for digestion. Following this, the study moves into the very-low-calorie diet (VLCD) phase, where participants consume approximately 800 kcal per day using formula meals tailored to meet their nutritional needs despite the calorie restriction. During this 12-week phase, changes in body weight, composition, and metabolic parameters are closely monitored. The final phase of the study is a 12-week weight maintenance period, during which the focus is on sustaining the achieved weight loss. In addition to RMR and dietary assessments, advanced techniques such as metabolomics are employed. Blood, urine, and saliva samples are collected to analyze metabolic profiles and identify potential hormonal biomarkers-such as leptin, FGF21, and adrenaline-that could further differentiate the "thrifty" and "spendthrift" phenotypes. Body composition is also assessed using methods like bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod). By correlating the changes in RMR with metabolic and hormonal markers, the study tests the hypothesis that individuals with a marked RMR decrease during fasting (the "thrifty" phenotype) may experience less weight loss during a hypocaloric diet compared to those with minimal RMR change (the "spendthrift" phenotype). If validated, this approach could allow clinicians to predict weight loss outcomes more accurately and tailor obesity treatments to the individual's unique metabolic profile.
CONDITIONS
Official Title
Metabolic Phenotyping for Personalized Obesity Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Morbid obesity with a BMI over 40 kg/m²
- Currently enrolled in a multimodal obesity therapy program at the University Hospital Schleswig-Holstein, Campus Kiel
You will not qualify if you...
- Diagnosis of type 1 or type 2 diabetes, fasting blood glucose over 125 mg/dL, or HbA1c above 6.5%
- Conditions affecting appetite or energy use such as Cushing's syndrome or uncontrolled thyroid disorders
- Gastrointestinal diseases impairing nutrient absorption like inflammatory bowel disease or malabsorption syndromes
- Psychiatric disorders influencing eating behavior including active depression, anorexia nervosa, bulimia nervosa, or borderline personality disorder
- Acute, unstable cardiovascular disease requiring hospitalization within the last 6 months
- Cancer treated within the past 5 years
- Chronic kidney disease stage IV or worse
- Active infectious diseases such as HIV or hepatitis
- Current use of nicotine or illicit drugs like amphetamines or cocaine
- Regular intense physical activity of 1 hour or more daily
- Presence of non-MRI-compatible metallic implants such as joint replacements or metal plates
- Pregnancy or breastfeeding
- Use of weight-loss medications
- Clinically relevant claustrophobia
- Any other condition considered by the investigator to interfere with participation or safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany, 24105
Actively Recruiting
Research Team
T
Tim Hollstein, PD Dr. med.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here